Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 16, 2026
- $426.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.87M in total
- 5
- 13F holdersQ2 2026, +29 vs. previous quarter
- 126
- 13F valueReported value at the end of Q2 2026
- $1.31B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $59.0K
- −86.6% year over year
- Net income, FY2025
- -$78.3M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $78.3M (132642.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.91M
- Shares sold short
- Change
- −3.05M
- −25.5% vs. previous
- Days to cover
- 2.09
- At average daily volume
Superinvestors holding AVTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AVTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Avalo Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:10 PM ET | Sep 16 | 2 days | Sullivan Christopher RyanChief Financial Officer | SSale | −12.4K | $16.33 | −$202.4K | −23.7%39.9K after | 10b5-1 |
| Sep 11, 2026 (view filing)4:10 PM ET | Sep 10 | 1 day | Sullivan Christopher RyanChief Financial Officer | SSale | −10.2K | $17.62 | −$179.5K | −20.3%39.9K after | 10b5-1 |
| Sep 1, 2026 (view filing)4:38 PM ET | Aug 28 | 4 days | Doyle MittieChief Medical Officer | SSale | −679 | $20.00 | −$13.6K | −1.3%51.8K after | 10b5-1 |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17-18 | 2 days | Sullivan Christopher RyanChief Financial Officer | SSale | −72.7K | $19.94 | −$1.45M | −64.6%39.9K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17 | 2 days | Doyle MittieChief Medical Officer | SSale | −1.00K | $20.00 | −$20.0K | −1.9%51.8K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:10 PM ET | Aug 11 | 1 day | Riley JenniferChief Strategy Officer | SSale | −2.65K | $19.59 | −$52.0K | −6.7%37.0K after | |
| Aug 12, 2026 (view filing)4:10 PM ET | Aug 10 | 2 days | Doyle MittieChief Medical Officer | SSale | −679 | $20.00 | −$13.6K | −1.3%51.8K after | 10b5-1 |
| Jul 29, 2026 (view filing)4:05 PM ET | Jul 27 | 2 days | Doyle MittieChief Medical Officer | SSale | −1.00K | $20.00 | −$20.0K | −1.9%51.8K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:05 PM ET | Jun 30 | 2 days | Doyle MittieChief Medical Officer | SSale | −4.65K | $20.00 | −$93.1K | −8.2%51.8K after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Doyle MittieChief Medical Officer | SSale | −1.45K | $18.00 | −$26.1K | −2.7%51.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 126 holdersThe largest institutional positions in Avalo Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 5,100,216 | $94.3M | 0.00% | +2,220,735+77.1% | Added |
| BlackRock, Inc. | 4,365,553 | $80.7M | 0.00% | +4,038,471+1,234.7% | Added |
| Deep Track Capital, LP | 3,610,000 | $66.7M | 0.98% | +3,610,000 | New |
| Caligan Partners LP | 3,163,866 | $58.5M | 2.82% | +1,528,843+93.5% | Added |
| TCG Crossover Management, LLC | 3,017,120 | $55.8M | 1.34% | +2,278,737+308.6% | Added |
| Affinity Asset Advisors, LLC | 2,900,000 | $53.6M | 2.62% | +1,559,160+116.3% | Added |
| State Street Corp | 2,889,287 | $53.4M | 0.00% | +2,817,633+3,932.3% | Added |
| Farallon Capital Management, L.L.C. | 2,498,000 | $46.2M | 0.27% | +1,582,000+172.7% | Added |
| Point72 Asset Management, L.P. | 2,387,026 | $44.1M | 0.07% | +1,470,884+160.6% | Added |
| Avoro Capital Advisors LLC | 2,333,333 | $43.1M | 0.39% | +923,333+65.5% | Added |
Holders of 5% or more of AVTX
See all 11 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Avalo Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G | 9.90%5.72M shares | New | Jun 18, 20261 filing | Jun 18, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G | 7.90%3.02M shares | New | May 12, 20261 filing | May 12, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G | 7.40%3.97M shares | New | Nov 13, 20261 filing | Nov 13, 2026 | SEC |
| Deep Track Capital, LP | 13G/A | 6.87%3.61M shares | +1.06 ppfrom 5.81% | Apr 5, 20244 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.50%3.42M shares | New | Jul 27, 20261 filing | Jul 27, 2026 | SEC |